ArticleEuropean journal of radiology open2025
The impact of pulmonary artery invasion on bronchial artery embolization in treating hemoptysis in lung cancer.
Article in European journal of radiology open, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed, 1 synthesis or guideline pooled it.
- Predictors of Recurrence Following Bronchial Artery Embolisation (BAE) for Haemoptysis: A Systematic Review and Evidence Synthesis Analyses Using SWiM Guidelines.Cardiovascular and interventional radiology · 2026Pooled it
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This study investigates the effect of pulmonary artery invasion on bronchial artery embolization (BAE) for the treatment of hemoptysis caused by lung cancer. A single-center retrospective analysis was conducted on the clinical data of 58 lung cancer patients who underwent BAE treatment for hemoptysis between July 2019 and July 2023. Based on preoperative CT angiography results, patients were divided into two groups: the pulmonary artery invasion group (n = 40) and the non-pulmonary artery invasion group (n = 18). The clinical characteristics, technical success rate, clinical success rate, complication rate, hemoptysis recurrence rate, and other factors were compared between the two groups. The prognostic factors for hemoptysis-free survival were analyzed using the Cox proportional hazards model. The results showed that, compared with the non-pulmonary artery invasion group, there was no significant difference in age (65.6 ± 8.2 vs. 67.2 ± 9.0, P = 0.52), gender (P = 0.67), Maximal tumor size (59.7 ± 26.0 vs. 51.6 ± 21.1, P = 0.25), the clinical success rate (85.0 % vs. 100.0 %, P = 0.16), the postoperative complication rate (15.0 % vs. 22.2 %) and so on between the two groups. However, the recurrence rate of hemoptysis one month after BAE was significantly higher in the pulmonary artery invasion group (60.0 % vs. 11.1 %, P < 0.01). The median hemoptysis-free survival time in the pulmonary artery invasion group was 28.5 days (IQR 54.3 days), which was significantly lower than 420.0 days (IQR 637.5 days) in the non-pulmonary artery invasion group (P < 0.01). Multivariate analysis showed that pulmonary artery invasion was an independent risk factor for hemoptysis recurrence after BAE (OR=18.46, 95 % CI: 6.37-53.49, P < 0.01). The study concluded that pulmonary artery invasion has a significant impact on hemoptysis recurrence after BAE in lung cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.